Magnanimi Lina Maria, De Berardinis Andrea, Esposito Maria, Fargnoli Maria Concetta
Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
General and Oncologic Dermatology Unit, San Salvatore Hospital, ASL 1 Abruzzo, L'Aquila, Italy.
Case Rep Dermatol. 2025 Feb 28;17(1):91-95. doi: 10.1159/000544703. eCollection 2025 Jan-Dec.
An increased risk of developing vitiligo has recently been described in patients with atopic dermatitis (AD). Vitiligo and AD can be associated because of shared pathogenetic pathways, including alterations in the Janus kinases/signal transducer and activator of transcription (JAK/STAT) signaling, suggesting JAK inhibitors as a promising new therapeutic approach in vitiligo.
We describe a 25-year-old woman diagnosed with AD since childhood and subsequent onset of slowly progressive vitiligo at the age of 16. Systemic therapy with JAK1 inhibitor upadacitinib 15 mg daily was started, after a medical and laboratory evaluation to exclude pregnancy and other contraindications. Progressive improvement of AD was observed after the first weeks of treatment with clinical remission at week 16. At the same time, clear improvement of vitiligo was observed with an almost complete remission achieved at week 28 of treatment.
The remission of both AD and vitiligo achieved with upadacitinib monotherapy supports the therapeutic utility of inhibition of JAK 1 signaling in these patients.
最近有研究表明，特应性皮炎（AD）患者患白癜风的风险增加。白癜风和AD可能由于共同的致病途径而相关，包括Janus激酶/信号转导和转录激活因子（JAK/STAT）信号通路的改变，这表明JAK抑制剂可能是治疗白癜风的一种有前景的新方法。
我们描述了一名25岁的女性，她自幼被诊断为AD，16岁时开始出现缓慢进展的白癜风。在进行医学和实验室评估以排除妊娠及其他禁忌证后，开始每日口服15mg JAK1抑制剂乌帕替尼进行全身治疗。治疗最初几周后观察到AD逐渐改善，第16周时临床缓解。同时，白癜风也明显改善，治疗第28周时几乎完全缓解。
乌帕替尼单药治疗使AD和白癜风均获缓解，这支持了抑制JAK 1信号通路在这些患者中的治疗作用。
